Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
about
Oral vasodilators for primary Raynaud's phenomenonPlatelet serotonin in systemic sclerosis.A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.The Effect of Lactic Acid Bacteria-fermented Soybean Milk Products on Carrageenan-induced Tail Thrombosis in Rats.The effect of local temperature versus sympathetic tone on digital perfusion in Raynaud's phenomenon.Cyanosis and Raynaud's phenomenon: the relation to underlying disease and venous abnormalities.Ketanserin: an effective treatment regimen for digital ischaemia in systemic sclerosis.Hemodynamic effects of prostacyclin infusions in healthy volunteers.Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon.Noninvasive hemodynamic assessment of vasospasm in patients with primary Raynaud's phenomenon.Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon.Digital blood pressure and flow measurements in patients with primary Raynaud's phenomenon.Influence of the menstrual cycle on Raynaud's phenomenon and on cold tolerance in normal women.Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.Effects of ketanserin, a 5-HT2-receptor antagonist, on the blood flow response to temperature changes in the diabetic foot.Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.Points: Treatment of Raynaud's phenomenon with ketanserin.Intra arterial ketanserin in peripheral vascular disease.
P2860
Q24202210-3C69B5AE-C7B2-43FB-BCC1-C9B5DFF6003AQ33561867-1CCB9F22-4AA4-4070-8FA6-9081A219062EQ33564034-3BEF6146-7C62-4E82-9EF0-CF57AA5413E7Q33666397-B9544D11-79EA-467C-93AD-BE1F179F7363Q34116461-40D6ECCA-FED9-459B-8497-B1E827DF29AEQ34766951-62872B59-232C-4BD5-A598-12F3E443FDE9Q36061884-AB7E8701-9893-4191-9381-19EC2D665BF9Q36421113-854743E5-0343-45CD-BD2D-E06195283A79Q39277981-F04473E3-4C52-4822-86CA-9162F700CEB7Q39303458-9AFF6E4E-6023-41DD-92FE-700EF7F9E9AFQ39304783-627C1223-F912-4FA4-92CD-6ED1D5ABDFB5Q39307272-031C92E5-CF33-4C68-9A80-A03573691FA4Q39317144-6D1962E0-41CC-41B0-806B-7733FA8D37ADQ39806660-CEB92E10-0D5D-42CE-AF21-8A13D4B8A643Q41352515-C5414960-A94F-4139-9ABC-16F098E9AF59Q41897297-88574E47-B8F1-47F8-9ED7-390B504D41ABQ43740421-E2F11C23-A3AB-43D8-93B6-4FE859DDFF84Q45990145-0B56766F-E034-4407-B974-0FF9CE5B3C12Q54147095-D93DFB34-E13C-49EF-A0D2-4CE74D1F5A2A
P2860
Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Treatment of Raynaud's phenome ...... e serotonin2 (5-HT2) receptor.
@en
Treatment of Raynaud's phenome ...... e serotonin2 (5-HT2) receptor.
@nl
type
label
Treatment of Raynaud's phenome ...... e serotonin2 (5-HT2) receptor.
@en
Treatment of Raynaud's phenome ...... e serotonin2 (5-HT2) receptor.
@nl
prefLabel
Treatment of Raynaud's phenome ...... e serotonin2 (5-HT2) receptor.
@en
Treatment of Raynaud's phenome ...... e serotonin2 (5-HT2) receptor.
@nl
P2860
P356
P1476
Treatment of Raynaud's phenome ...... e serotonin2 (5-HT2) receptor.
@en
P2093
Jageneau AH
Seibold JR
P2860
P304
P356
10.1002/ART.1780270204
P577
1984-02-01T00:00:00Z